Athena Global Technologies Fund Raise of ₹5.88 Cr

Athena Global Technologies Other Announcement

Athena Global Technologies Ltd submitted its quarterly shareholding pattern statement in compliance with SEBI regulations for the period ending September 2026.

Athena Global Technologies Annual General Meeting

Athena Global Technologies Limited conducted its 34th Annual General Meeting on September 30, 2026, where shareholders discussed financial statements and the re-appointment of a director.

Athena Global Technologies Business Update

Athena Global Technologies has leased out premises at Phoenix Centaurus, Hyderabad, for an annual rent of ₹11.19 Crore. The lease agreement spans 5 years.

Value

₹11.19 Cr

Execution

5 years

Athena Global Technologies Annual General Meeting

Athena Global Technologies Limited announced its 34th Annual General Meeting scheduled for 30th September 2026. The filing includes the company's Annual Report for 2025-26.

Athena Global Technologies Q1 FY27 Results: Net Loss of ₹3.2 Cr, Loss Narrows

Athena Global Technologies Ltd reported revenue from operations of ₹4.8 Cr (+60.0% YoY) and a net loss of ₹3.2 Cr for Q1 FY27.

Key figure

Net loss ₹3.2 Cr

Athena Global Technologies Board Meeting Date

Athena Global Technologies will hold a Board Meeting on August 14, 2026, to consider and approve its Q1 financial results for the quarter ended June 30, 2026.

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.

Gujarat Inject (Kerala) Fund Raise of ₹3 Cr

Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.

Value

₹3.00 Cr